Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy.
Benign prostatic hyperplasia is generally regarded as being a hormone-dependent disorder. The inductive action of stromal elements on the glandular epithelium and the demonstrable estrogen sensitivity of the stroma suggest that estrogens may play a role in the etiology of prostatic hyperplasia. This hypothesis forms the theoretical basis for the proposed use of aromatase inhibitors in treatment of this disorder.
Henderson
D
D
Research Laboratories of Schering AG, Berlin/Bergkamen, FRG.
Habenicht
U F
UF
Nishino
Y
Y
el Etreby
M F
MF
D047072:Aromatase Inhibitors; D004967:Estrogens / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology
D047072:Aromatase Inhibitors; D004967:Estrogens